Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation combined with regorafenib and continued PD-1 inhibitor after first-line PD-1 resistance in hepatocellular carcinoma
ChiCTR2500097463Phase 2Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Objective response rate. Started Feb 2025; status: recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500097463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097463.